Patient-Based Therapeutics
AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas



Latest News
AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial
Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, is pleased to announce its sponsorship of the Gordon Research Seminar and Conference on "Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases Mechanisms, Modeling and Translational Therapeutics."